Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 5:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: RP11 Clear all

Completed Phase 1 Interventional

SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects

NCT05902962

View directory record Official record

Conditions: Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy, RP11
Interventions: VP-001; Drug
Lead sponsor: PYC Therapeutics; Industry
Eligibility: 18 Years and older

Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Jacksonville, Florida • Miami, Florida • Ann Arbor, Michigan + 3 more

Source: ClinicalTrials.gov public record

Updated Apr 12, 2026 · Synced May 22, 2026, 5:34 AM EDT

Completed Phase 1 Interventional

MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)

NCT06455826

View directory record Official record

Conditions: Retinitis Pigmentosa 11, Retinal Degeneration, Eye Diseases, Retinal Disease, Retinal Dystrophies
Interventions: VP-001; Drug
Lead sponsor: PYC Therapeutics; Industry
Eligibility: 12 Years and older

Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 5
States / cities: Jacksonville, Florida • Ann Arbor, Michigan • Portland, Oregon + 2 more

Source: ClinicalTrials.gov public record

Updated Apr 12, 2026 · Synced May 22, 2026, 5:34 AM EDT

Active, not recruiting No phase listed Observational

Natural History of PRPF31 Mutation-Associated Retinal Dystrophy

NCT05573984

View directory record Official record

Conditions: Retinitis Pigmentosa, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Dystrophy Rod, Retinal Dystrophy Rod Progressive
Interventions: Not listed
Lead sponsor: PYC Therapeutics; Industry
Eligibility: 10 Years and older

Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 5
States / cities: San Francisco, California • Jacksonville, Florida • Ann Arbor, Michigan + 2 more

Source: ClinicalTrials.gov public record

Updated Apr 12, 2026 · Synced May 22, 2026, 5:34 AM EDT

Recruiting Phase 1Phase 2 Interventional

A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001

NCT06852963

View directory record Official record

Conditions: Retinitis Pigmentosa 11, Retinal Degeneration, Retinal Disease, Eye Diseases Hereditary, Retinal Dystrophies
Interventions: VP-001; Drug
Lead sponsor: PYC Therapeutics; Industry
Eligibility: 18 Years and older

Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Jacksonville, Florida • Miami, Florida • Ann Arbor, Michigan + 3 more

Source: ClinicalTrials.gov public record

Updated Dec 1, 2025 · Synced May 22, 2026, 5:34 AM EDT